Kristen Grable, MD
Psychiatry · Dallas, TXNPI 1720001118
Payments from drug & device makers
Across 170 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$456
- Neurocrine Biosciences, Inc.$429
- Teva Pharmaceuticals USA, Inc.$394
- E.r. Squibb & Sons, L.L.C.$334
- Indivior Inc.$310
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
- plus $802 from 12 others
What the payments were for
- Food & beverage$2,951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $456 |
| Neurocrine Biosciences, Inc. | 19 | $429 |
| Teva Pharmaceuticals USA, Inc. | 22 | $394 |
| E.r. Squibb & Sons, L.L.C. | 21 | $334 |
| Indivior Inc. | 21 | $310 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $224 |
| Otsuka America Pharmaceutical, Inc. | 11 | $212 |
| Johnson & Johnson | 12 | $185 |
| Alkermes, Inc. | 6 | $113 |
| Vanda Pharmaceuticals Inc. | 6 | $104 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Eisai Inc. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Merck | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
How this compares
$2,951 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 125 | $1,054,632 |
| Invega SustennaPaliperidone Palmitate | 241 | $760,503 |
| AustedoDeutetrabenazine | 97 | $546,740 |
| Abilify MaintenaAripiprazole | 96 | $255,785 |
| Invega TrinzaPaliperidone Palmitate | 23 | $219,276 |
| Austedo XrDeutetrabenazine | 25 | $169,092 |
| AristadaAripiprazole Lauroxil | 45 | $135,344 |
| VraylarCariprazine Hcl | 43 | $63,248 |
| CaplytaLumateperone Tosylate | 21 | $35,087 |
| BelsomraSuvorexant | 77 | $34,242 |
| Risperidone ErRisperidone Microspheres | 16 | $31,946 |
| TrintellixVortioxetine Hydrobromide | 45 | $24,862 |
| Clozapine | 120 | $8,620 |
| Quetiapine Fumarate | 414 | $7,085 |
| Aripiprazole | 230 | $6,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $429 | $1,054,632125 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal | $185 | $982,655276 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $394 | $715,832122 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $212 | $255,78596 claims |
| Alkermes, Inc.Aristada | $113 | $135,34445 claims |
| AbbVieVraylar | $456 | $63,24843 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $224 | $35,08721 claims |
| MerckBelsomra | $19 | $34,24277 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $24 | $24,86245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.